Skip to content

Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry.

Denis S Theobald, Giselher Fritschi, Hans H Maurer

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences February 1, 2007 DOI: 10.1016/j.jchromb.2006.08.049 via PubMed

Summary

AI-generated from the abstract

The designer drug 2C-B is extensively metabolized and excreted mainly as metabolites in urine. In rats, a systematic toxicological analysis using full-scan GC-MS detected the O-demethyl deaminohydroxy metabolite and two isomers of the O-demethyl metabolite after a common drug abuser's dose. The authors suggest that, assuming similar metabolism in humans, this procedure should be suitable for proving 2C-B intake in human urine.

Study at a glance

Characteristics Experimental study Peer reviewed
Population Rat urine
Intervention 2C-B
Dose common drug abusers' dose
Keywords Drug detection Drug testing Drug screening Substance detection Illicit drug identification
Citations 37
Key finding The GC-MS procedure can detect 2C-B metabolites in rat urine and should be suitable for human urine.

Abstract

The phenethylamine-derived designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) is known to be extensively metabolized in various species including humans. In rat urine, 2C-B was found to be excreted mainly via its metabolites. In the current study, the toxicological detection of these metabolites in the authors' systematic toxicological analysis (STA) procedure was examined. The STA procedure using full-scan GC-MS allowed proving an intake of a common drug abusers' dose of 2C-B by detection of the O-demethyl deaminohydroxy and two isomers of the O-demethyl metabolites in rat urine. Assuming similar metabolism, the described STA procedure should be suitable for proof of an intake of 2C-B in human urine.

Comments

No comments yet.

Log in to comment